2024-11-0920202006-016510.21010/ajid.v14i2.72-s2.0-85090636335https://hdl.handle.net/20.500.14288/2966Background: human immunodeficiency virus (HIV) is a global health concern with major risks for opportunistic infections and predisposition to malignancies including Kaposi sarcoma associated with Human Herpes Virus-8 (HHV-8) and non-Hodgkin lymphoma (NHL) commonly associated with Epstein Barr Virus (EBV). Although the exact mechanisms of predisposition to certain malignancies are unclear, HIV (+) cancer patients typically have poorer prognosis. Materials and methods: we included all five HIV positive NHL patients receiving antiretroviral therapy (ART) and chemotherapy in our clinic and aim to determine their follow-up outcomes associated with ART. Results: the use of ART in conjunction with chemotherapy regimens lead to better therapeutic outcome in our cases with no mortality over three years of follow-up despite high rates of poor prognostic factors and studies demonstrating 1-year survival rates of approximately 30% in HIV-associated lymphoma. No significant adverse effect has been recorded. Conclusion: we recommend use of ART along with chemotherapy regimens in HIV positive lymphoma patients for better treatment response.pdfMedicineAntiretroviral therapyJournal Articlehttps://pubmed.ncbi.nlm.nih.gov/33884350/Q4NOIR02427